Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 57Myelodysplastic Syndromes 32Leukemia, Myelomonocytic, Chronic 15Leukemia 15Recurrence 8Multiple Myeloma 8Neoplasms 6Primary Myelofibrosis 5Myeloproliferative Disorders 5Lymphoma, Non-Hodgkin 5Hematologic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Lymphoma, Large B-Cell, Diffuse 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Lymphoma, Follicular 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms, Plasma Cell 2Neoplasm, Residual 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid 2Hodgkin Disease 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Anemia, Refractory, with Excess of Blasts 2

Interventions

Carboplatin 25Etoposide 23Cisplatin 16pembrolizumab 9Topotecan 9atezolizumab 7Pemetrexed 7Nivolumab 7Radiosurgery 6Irinotecan 5durvalumab 4Paclitaxel 4Gemcitabine 4Albumin-Bound Paclitaxel 4rovalpituzumab tesirine 3etoposide phosphate 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Cyclophosphamide 3vistusertib 2roniciclib 2pelcitoclax 2pazopanib 2epacadostat 2amrubicin 2Vorinostat 2Radiation 2Fluorodeoxyglucose F18 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Small Cell Lung Carcinoma × Azacitidine × Clear all
NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
116 enrolled 36 charts
MyeloidOther hematologic neoplasmThoracic

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡